ReviewFrontiers in immunology2015
Lymphoma Immunotherapy: Current Status.
Review in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.British journal of clinical pharmacology · 2019Trial
- Investigation of PD-L1 Expression in Various Non-Hodgkin's B-cell Lymphomas.Iranian journal of pathology · 2025Article
- CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain.Blood advances · 2022Article
- Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review.Future oncology (London, England) · 2022Review
- The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines.Cancer treatment reviews · 2022Review
- A Novel Multiepitope Vaccine Against Bladder Cancer Based on CTL and HTL Epitopes for Induction of Strong Immune Using Immunoinformatics Approaches.International journal of peptide research and therapeutics · 2022Article
- Research and application of hydrostatic high pressure in tumor vaccines (Review).Oncology reports · 2021Review
- Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.Frontiers in cell and developmental biology · 2021Review
- Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma.Frontiers in veterinary science · 2021Review
- Secondary Metabolites from the Fungus Dictyosporium sp. and Their MALT1 Inhibitory Activities.Journal of natural products · 2019Article
- Immune targeting of the microenvironment in classical Hodgkin's lymphoma: insights for the hematologist.Therapeutic advances in hematology · 2019Review
- New developments in immunotherapy for lymphoma.Cancer biology & medicine · 2018Article
- The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.Oncotarget · 2018Article
- Microenvironment Cell Contribution to Lymphoma Immunity.Frontiers in oncology · 2018Review
- How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.Frontiers in immunology · 2018Review
- Article
- Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.Cancer immunology research · 2017Article
- Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10.Cancer immunology, immunotherapy : CII · 2017Article
- Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.European journal of nuclear medicine and molecular imaging · 2017Review
- Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.Journal of translational medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rationale to treat lymphomas with immunotherapy comes from long-standing evidence on their distinctive immune responsiveness. Indolent B-cell non-Hodgkin lymphomas, in particular, establish key interactions with the immune microenvironment to ensure prosurvival signals and prevent antitumor immune activation. However, reports of spontaneous regressions indicate that, under certain circumstances, patients develop therapeutic antitumor immunity. Several immunotherapeutic approaches have been thus developed to boost these effects in all patients. To date, targeting CD20 on malignant B cells with the antibody rituximab has been the most clinically effective strategy. However, relapse and resistance prevent to cure approximately half of B-NHL patients, underscoring the need of more effective therapies. The recognition of B-cell receptor variable regions as B-NHL unique antigens promoted the development of specific vaccines to immunize patients against their own tumor. Despite initial promising results, this strategy has not yet demonstrated a sufficient clinical benefit to reach the regulatory approval. Several novel agents are now available to stimulate immune effector functions or counteract immunosuppressive mechanisms, such as engineered antitumor T cells, co-stimulatory receptor agonist, and immune checkpoint-blocking antibodies. Thus, multiple elements can now be exploited in more effective combinations to break the barriers for the induction of anti-lymphoma immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.